Followers | 129 |
Posts | 2150 |
Boards Moderated | 1 |
Alias Born | 12/27/2007 |
Friday, June 26, 2020 7:39:30 AM
SNGX =MCap $50 Mil / 3 Cancer Drugs in Phase 3 with Data in Q4 / COVID 19 VACCINE programm with first data soon / Undiscovered
Soligenix (SNGX)
Market Cap $50 million
Price 1.90
Presentation
http://ir.soligenix.com/download/Soligenix+Corporate+Presentation+06.24.20FINAL.pdf
Soligenix Completes Enrollment in its Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis
https://finance.yahoo.com/news/soligenix-completes-enrollment-pivotal-phase-110000377.html
Final top-line results expected Q4 2020
SNGX: Q&A on COVID-19 Vaccine Candidate CiVax™…
https://finance.yahoo.com/news/sngx-q-covid-19-vaccine-093900828.html
As a reminder, following the positive topline data presented by the company for SGX-301 in CTCL, we continue to anticipate Phase 3 data for SGX-942 in oral mucositis in the fourth quarter of 2020. The company will also be joining the Russell Microcap Index effective June 29th, 2020, which should help to increase visibility within the investment community. Our current valuation is $12 per share.
Recent SNGX News
- Soligenix to Present at Upcoming Conferences • PR Newswire (US) • 05/06/2024 11:30:00 AM
- Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa • PR Newswire (US) • 04/25/2024 11:30:00 AM
- Soligenix Announces Pricing of $4.75 Million Public Offering • PR Newswire (US) • 04/18/2024 12:30:00 PM
- FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection • PR Newswire (US) • 04/15/2024 11:30:00 AM
- FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection • PR Newswire (US) • 04/11/2024 11:30:00 AM
- Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency • PR Newswire (US) • 04/03/2024 11:30:00 AM
- Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results • PR Newswire (US) • 03/15/2024 11:30:00 AM
- Soligenix Announces Formation of Behçet's Disease Medical Advisory Board • PR Newswire (US) • 02/08/2024 12:30:00 PM
- Soligenix to Present at The Microcap Conference • PR Newswire (US) • 01/25/2024 12:30:00 PM
- FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease • PR Newswire (US) • 01/08/2024 12:30:00 PM
- Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis • PR Newswire (US) • 01/04/2024 12:30:00 PM
- Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses • PR Newswire (US) • 01/02/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2023 09:05:29 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/18/2023 05:15:36 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:10:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:10:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:10:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/15/2023 09:10:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/15/2023 09:03:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 10:12:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 10:11:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 10:10:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/08/2023 10:10:16 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 12/08/2023 09:05:59 PM
- "HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma" Published in Frontiers in Drug Discovery • PR Newswire (US) • 12/01/2023 12:30:00 PM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM